NeuroSense Advances PrimeC Toward Potential ALS Approval
TEL AVIV, Israel, Aug. 31, 2026 NeuroSense Therapeutics Ltd. announced an accelerated and capital-efficient development strategy for PrimeC, its...
ALS
Advertisement
Cellenkos Wins FDA Fast Track for CK0803 in ALS
Houston, Texas, Aug 27, 2026 Cellenkos, Inc. has received FDA Fast Track designation for CK0803, an investigational allogeneic, cord...
Leal Therapeutics Advances LTX-001 in Schizophrenia Trial
Worcester, Massachusetts, August 17, 2026 Leal Therapeutics, a clinical-stage biopharmaceutical company developing neuro-metabolic therapeutics for central nervous system disorders,...
Clene Advances CNM-Au8 Toward ALS Accelerated Approval
SALT LAKE CITY, Utah, August 10, 2026 Clene Inc. announced new biomarker analyses for CNM-Au8 that will be included...
Amylyx Pharmaceuticals Advances Avexitide Toward Phase 3 Data
CAMBRIDGE, Mass., August 6, 2026 Amylyx Pharmaceuticals reported its second quarter 2026 financial results, highlighting significant progress across its...
Advertisements
CervoMed Shares Neflamapimod Development Update
BOSTON, August 5, 2026 CervoMed announced that its management team will participate in a fireside chat and investor meetings...
Ractigen Therapeutics Closes $31M Financing to Advance saRNA Pipeline
NANTONG, China, July 29, 2026 Ractigen Therapeutics has successfully closed a financing round exceeding $31 million (over RMB 200...
AB Science Prioritizes AML and ALS Programs
PARIS, July 10, 2026 AB Science announced a major strategic update to its clinical development pipeline, confirming that it...
NKGen Biotech to Highlight Troculeucel Alzheimer’s Program at BIOCHINA Forum
SANTA ANA, Calif., July 2, 2026 NKGen Biotech announced that Chairman and Chief Executive Officer Paul Y. Song, M.D.,...
Chiesi, Arbor Secure EU Orphan Status for ABO-101
PARMA, Italy & CAMBRIDGE, Mass., June 25, 2026 Chiesi Group and Arbor Biotechnologies have achieved a significant regulatory milestone...
Advertisement
